Patent Publication Number: US-6040175-A

Title: AMPA-binding human GluR2 receptors

Description:
This application is a divisional of application Ser. No. 08/242,344, filed May 13, 1994, which is a continuation of application Ser. No. 07/896,437, filed Jun. 10, 1992, abandoned. 
    
    
     FIELD OF THE INVENTION 
     This invention is concerned with applications of recombinant DNA technology in the field of neurobiology. More particularly, the invention relates to the cloning and expression of DNA coding for excitatory amino acid (EAA) receptors, especially human EAA receptors. 
     BACKGROUND TO THE INVENTION 
     In the mammalian central nervous system (CNS), the transmission of nerve impluses is controlled by the interaction between a neurotransmitter substance released by the &#34;sending&#34; neuron which binds to a surface receptor on the &#34;receiving&#34; neuron to cause excitation thereof. L-glutamate is the most abundant neurotransmitter in the CNS, and mediates the major excitatory pathway in vertebrates. Glutamate is therefore referred to as an excitatory amino acid (EAA) and the receptors which respond to it are variously referred to as glutamate receptors, or more commonly as EAA receptors. 
     Using tissues isolated from mammalian brain, and various synthetic EAA receptor agonists, knowledge of EAA receptor pharmacology has been refined somewhat. Members of the EAA receptor family are now grouped into three main types based on differential binding to such agonists. One type of EAA receptor, which in addition to glutamate also binds the agonist NMDA (N-methyl-D-aspartate), is referred to as the NMDA type of EAA receptor. Two other glutamate-binding types of EAA receptor, which do not bind NMDA, are named according to their preference for binding with two other EAA receptor agonists, namely AMPA (alpha-amino-3-hydroxy-5-methyl-isoxazole-4-propionate), and kainate. Particularly, receptors which bind glutamate but not NMDA, and which bind with greater affinity to kainate than to AMPA, are referred to as kainate type EAA receptors. Similarly, those EAA receptors which bind glutamate but not NMDA, and which bind AMPA with greater affinity than kainate are referred to as AMPA type EAA receptors. 
     The glutamate-binding EAA receptor family is of great physiological and medical importance. Glutamate is involved in many aspects of long-term potentiation (learning and memory), in the development of synaptic plasticity, in epileptic seizures, in neuronal damage caused by ischemia following stroke or other hypoxic events, as well as in other forms of neurodegenerative processes. However, the development of therapeutics which modulate these processes has been very difficult, due to the lack of any homogeneous source of receptor material with which to discover selectively binding drug molecules, which interact specifically at the interface of the EAA receptor. The brain derived tissues currently used to screen candidate drugs are heterogeneous receptor sources, possessing on their surface many receptor types which interfere with studies of the EAA receptor/ligand interface of interest. The search for human therapeutics is further complicated by the limited availability of brain tissue of human origin. It would therefore be desirable to obtain cells that are genetically engineered to produce only the receptor of interest. With cell lines expressing cloned receptor genes, a substrate which is homogeneous for the desired receptor is provided, for drug screening programs. 
     Very recently, genes encoding substituent polypeptides of EAA receptors from non-human sources, principally rat, have been discovered. Hollmann et al., Nature 342: 643, 1989 described the isolation from rat of a gene referred to originally as GluR-K1 (but now called simply GluR1). This gene encodes a member of the rat EAA receptor family, and was originally suspected as being of the kainate type. Subsequent studies by Keinanen et al., Science 249: 556, 1990, showed, again in rat, that a gene called GluR-A, which was in fact identical to the previously isolated GluR1, in fact encodes a receptor not of the kainate type, but rather of the AMPA type. These two groups of researchers have since reported as many as five related genes isolated from rat sources. Boulter et al., Science 249: 1033, 1990, revealed that, in addition to GluR1, the rat contained 3 other related genes, which they called GluR2, GluR3, and GluR4, and Bettler et al., Neuron 5: 583. 1990 described GluR5. Keinanen et al., supra, described genes called GluR-A, GluR-B, GluR-C and GluR-D which correspond precisely to GluR1, GluR2, GluR3 and GluR4 respectively. Sommer et al., Science 249: 1580, 1990 also showed, for GluR-A, GluR-B, GluR-C and GluR-D two alternatively spliced forms for each gene. These authors, as well as Monyer et al., Neuron 6: 799, 1991 were able to show that the differently spliced versions of these genes were differentially expressed in the rat brain. In addition to the isolation of these AMPA receptor genes, several studies have more recently attempted to determine the ion-gating properties of different mixtures of the known receptors (Nakanishi et al., Neuron 5: 569, 1990; Hollmann et al., Science 252: 851, 1991; Verdoorn et al., Science 252: 1715, 1991; and see WO 91/06648). 
     There has emerged from these molecular cloning advances a better understanding of the structural features of EAA receptors and their subunits, as they exist in the rat brain. According to the current model of EAA receptor structure, each is heteromeric in structure, consisting of individual membrane-anchored subunits, each having four transmembrane regions, and extracellular domains that dictate ligand binding properties to some extent and contribute to the ion-gating function served by the receptor complex. Keinanen et al, supra, have shown for example that each subunit of the rat GluR receptor, including those designated GluR-A, GluR-B, GluR-C and GluR-D, display cation channel activity gated by glutamate, by AMPA and by kainate, in their unitary state. When expressed in combination however, for example GluR-A in combination with GluR-B, gated ion channels with notably larger currents are produced by the host mammalian cells. 
     In the search for therapeutics useful to treat CNS disorders in humans, it is highly desirable of course to provide a screen for candidate compounds that is more representative of the human situation than is possible with the rat receptors isolated to date. It is particularly desirable to provide cloned genes coding for human receptors, and cell lines expressing those genes, in order to generate a proper screen for human therapeutic compounds. These, accordingly, are objects of the present invention. 
     SUMMARY OF THE INVENTION 
     The present invention provides an isolated polynucleotide that codes for an AMPA-binding human EAA receptor. By providing polynucleotide that codes specifically for a CNS receptor native to humans, the present invention provides means for evaluating the human nervous system, and particularly for assessing potentially therapeutic interactions between the AMPA-binding human EAA receptors and selected natural and synthetic ligands. 
     In one of its aspects, the present invention provides an isolated polynucleotide comprising nucleic acids arranged in a sequence that encodes for the human EAA receptor herein designated the human GluR2B receptor. Alternatively, the polynucleotide may code for an AMPA-binding fragment of the human GluR2B receptor, or for an AMPA-binding variant of the human GluR2B receptor. In various specific embodiments of the present invention, the polynucleotide consists of DNA e.g. cDNA, or of RNA e.g. messenger RNA. In other embodiments of the present invention, the polynucleotide may be coupled to a reporter molecule, such as a radioactive label, for use in autoradiographic studies of human GluR2B receptor tissue distribution. In further embodiments of the present invention, fragments of the polynucleotides of the invention, including radiolabelled versions thereof, may be employed either as probes for detection of glutamate receptor-encoding polynucleotides, as primers appropriate for amplifying such polynucleotides present in a biological specimen, or as templates for expression of GluR2B receptor or an AMPA-binding fragment or variant thereof. 
     According to another aspect of the present invention, there is provided a cellular host having incorporated therein a polynucleotide of the present invention. In embodiments of the present invention, the polynucleotide is a DNA molecule and is incorporated for expression and secretion in the cellular host, to yield a functional, membrane-bound human GluR2B receptor. In other embodiments of the present invention, the polynucleotide is an RNA molecule which is incorporated in the cellular host to yield the human GluR2B receptor as a functional, membrane-bound product of translation. 
     According to another aspect of the invention, there is provided a process for obtaining a substantially homogeneous source of a human EAA receptor useful for performing ligand binding assays, which comprises the steps of culturing a genetically engineered cellular host of the invention, and then recovering the cultured cells. Optionally, the cultured cells may be treated to obtain membrane preparations thereof, for use in the ligand binding assays. 
     According to another aspect of the present invention, there is provided a method for assaying a substance for binding to a human EAA receptor, in which the substance is incubated under appropriate conditions with a human GluR2B receptor source, i.e., a cellular host of the invention or a membrane preparation derived therefrom, and then determining the extent of binding between the substance and the receptor source. 
    
    
     These and other aspects of the invention are now described in greater detail with reference to the accompanying drawings, in which: 
     BRIEF DESCRIPTION OF THE DRAWINGS 
     FIGS. 1(A)-1(K) provide a DNA sequence (SEQ ID NO:1) coding for the human GluR2B receptor, and the amino acid sequence (SEQ ID NO:2) thereof; 
     FIG. 2 depicts the strategy employed in cloning the human GluR2B receptor-encoding DNA illustrated in FIGS. 1(A)-1(K); 
     FIG. 3 depicts the strategy employed in generating recombinant DNA expression constructs incorporating the receptor-encoding DNA; 
     FIG. 4 illustrates the AMPA-binding property of the human GluR2B receptor. 
    
    
     DETAILED DESCRIPTION OF THE INVENTION AND ITS PREFERRED EMBODIMENTS 
     The invention relates to human CNS receptors of the AMPA-binding type, and provides isolated polynucleotides that code for such receptors. The term &#34;isolated&#34; is used herein with reference to intact polynucleotides that are generally less than about 4,000 nucleotides in length, more suitably less than about 3,000 nucleotides in length, and which are otherwise isolated from DNA coding for other human proteins. 
     In the present context, human CNS receptors of the AMPA-binding type exhibit a characteristic ligand binding profile, which reveals glutamate binding and relatively greater affinity for binding AMPA than for binding other CNS receptor ligands such as kainate, glutamate and their closely related analogues. 
     In the present specification, an AMPA-binding receptor is said to be &#34;functional&#34; if a cellular host producing it exhibits de novo channel activity when exposed appropriately to AMPA, as determined by the established electrophysiological assays described for example by Hollman et al, supra, or by any other assay appropriate for detecting conductance across a cell membrane. 
     The human GluR2B receptor of the invention possess structural features characteristic of the EAA receptors in general, including extracellular N- and C-terminal regions, as well as four internal hydrophobic domains which serve to anchor the receptor within the cell surface membrane. More specifically, GluR2B receptor is a protein characterized structurally as a single polypeptide chain that is produced initially in precursor form bearing a 21 amino acid residue N-terminal signal peptide, and is transported to the cell surface in mature form, lacking the signal peptide and consisting of 862 amino acids arranged in the sequence illustrated, by single letter code, in FIGS. 1(A)-1(K) (SEQ ID NO:1 and 2). Unless otherwise stated, the term human GluR2B receptor refers to the mature form of the receptor, and amino acid residues of the human GluR2B receptor are accordingly numbered with reference to the mature protein sequence. With respect to structural domains of the receptor, hydropathy analysis reveals four putative transmembrane domains, one spanning residues 525-544 inclusive (TM-1), another spanning residues 571-589 (TM-2), a third spanning residues 600-618 (TM-3) and the fourth spanning residues 792-812 (TM-4). Based on this assignment, it is likely that the human GluR2B receptor structure, in its natural membrane-bound form, consists of a 524 amino acid N-terminal extracellular domain, followed by a hydrophobic region containing four transmembrane domains and an extracellular, 50 amino acid C-terminal domain. 
     Binding assays performed with various ligands, and with membrane preparations derived from mammalian cells engineered genetically to produce the human GluR2B receptor in membrane-bound form indicate that GluR2B binds selectively to AMPA, relative particularly to kainate and NMDA. This feature, coupled with the medically significant connection between AMPA-type receptors and neurological disorders and disease indicate that the present receptor, and AMPA-binding fragments and variants thereof, will serve as valuable tools in the screening and discovery of ligands useful to modulate in vivo interactions between such receptors and their natural ligand, glutamate. Thus, a key aspect of the present invention resides in the construction of cells that are engineered genetically to produce human GluR2B receptor, to serve as a ready and homogeneous source of receptor for use in in vitro ligand binding and/or channel activation assays. 
     For use in the ligand binding assays, it is desirable to construct by application of genetic engineering techniques a mammalian cell that produces human GluR2B receptor as a heterologous, membrane-bound product. According to one embodiment of the invention, the construction of such engineered cells is achieved by introducing into a selected host cell a recombinant DNA construct in which DNA coding for a secretable form of the human GluR2B receptor, i.e. a form bearing its native signal peptide or a functional, heterologous equivalent thereof, is linked operably with expression controlling elements that are functional in the selected host to drive expression of the receptor-encoding DNA, and thus elaborate the desired human GluR2B receptor protein. Such cells are herein characterized as having the receptor-encoding DNA incorporated &#34;expressibly&#34; therein. The receptor-encoding DNA is referred to as &#34;heterologous&#34; with respect to the particular cellular host if such DNA is not naturally found in the particular host. The particular cell type selected to serve as host for production of the human GluR2B receptor can be any of several cell types currently available in the art, but should not of course be a cell type that in its natural state elaborates a surface receptor that can bind excitatory amino acids, and so confuse the assay results sought from the engineered cell line. Generally, such problems are avoided by selecting as host a non-neuronal cell type, and can further be avoided using non-human cell lines, as is conventional. It will be appreciated that neuronal- and human-type cells may nevetheless serve as expression hosts, provided that &#34;background&#34; binding to the test ligand is accounted for in the assay results. 
     According to one embodiment of the present invention, the cell line selected to serve as host for human GluR2B receptor production is a mammalian cell. Several types of such cell lines are currently available for genetic engineering work, and these include the chinese hamster ovary (CHO) cells for example of K1 lineage (ATCC CCL 61) including the Pro5 variant (ATCC CRL 1281); the fibroblast-like cells derived from SV40-transformed African Green monkey kidney of the CV-1 lineage (ATCC CCL 70), of the COS-1 lineage (ATCC CRL 1650) and of the COS-7 lineage (ATCC CRL 1651); murine L-cells, murine 3T3 cells (ATCC CRL 1658), murine C127 cells, human embryonic kidney cells of the 293 lineage (ATCC CRL 1573), human carcinoma cells including those of the HeLa lineage (ATCC CCL 2), and neuroblastoma cells of the lines IMR-32 (ATCC CCL 127), SK-N-MC (ATCC HTB 10) and SK-N-SH (ATCC HTB 11). 
     A variety of gene expression systems have been adapted for use with these hosts and are now commercially available, and any one of these systems can be selected to drive expression of the human GluR3 receptor-encoding DNA. These systems, available typically in the form of plasmidic vectors, incorporate expression cassettes the functional components of which include DNA constituting expression controlling sequences, which are host-recognized and enable expression of the receptor-encoding DNA when linked 5&#39; thereof. The systems further incorporate DNA sequences which terminate expression when linked 3&#39; of the receptor-encoding region. Thus, for expression in the selected mammalian cell host, there is generated a recombinant DNA expression construct in which DNA coding for the receptor in secretable form is linked with expression controlling DNA sequences recognized by the host, and which include a region 5&#39; of the receptor-encoding DNA to drive expression, and a 3&#39; region to terminate expression. The plasmidic vector harbouring the recombinant DNA expression construct typically incorporates such other functional components as an origin of replication, usually virally-derived, to permit replication of the plasmid in the expression host and desirably also for plasmid amplification in a bacterial host, such as E.coli. To provide a marker enabling selection of stably transformed recombinant cells, the vector will also incorporate a gene conferring some survival advantage on the transformants, such as a gene coding for neomycin resistance in which case the transformants are plated in medium supplemented with neomycin. 
     Included among the various recombinant DNA expression systems that can be used to achieve mammalian cell expression of the receptor-encoding DNA are those that exploit promoters of viruses that infect mammalian cells, such as the promoter from the cytomegalovirus (CMV), the Rous sarcoma virus (RSV), simian virus (SV40), murine mammary tumor virus (MMTV) and others. Also useful to drive expression are promoters such as the LTR of retroviruses, insect cell promoters such as those regulated by temperature, and isolated from Drosophila, as well as mammalian gene promoters such as those regulated by heavy metals i.e. the metalothionein gene promoter, and other steroid-inducible promoters. 
     For incorporation into the recombinant DNA expression vector, DNA coding for the human GluR2B receptor, or an AMPA-binding fragment or variant thereof, can be obtained by applying selected techniques of gene isolation or gene synthesis. As described in more detail in the examples herein, the human GluR28B receptor is encoded within the genome of human brain tissue, and can therefore be obtained from human DNA libraries by careful application of conventional gene isolation and cloning techniques. This typically will entail extraction of total messenger RNA from a fresh source of human brain tissue, preferably cerebellum or hippocampus tissue, followed by conversion of message to cDNA and formation of a library in for example a bacterial plasmid, more typically a bacteriophage. Such bacteriophage harbouring fragments of the human DNA are typically grown by plating on a lawn of susceptible E. coli bacteria, such that individual phage plaques or colonies can be isolated. The DNA carried by the phage colony is then typically immobilized on a nitrocellulose or nylon-based hybridization membrane, and then hybridized, under carefully controlled conditions, to a radioactively (or otherwise) labelled oligonucleotide probe of appropriate sequence to identify the particular phage colony carrying receptor-encoding DNA or fragment thereof. Typically, the gene or a portion thereof so identified is subcloned into a plasmidic vector for nucleic acid sequence analysis. 
     In a specific embodiment of the invention, the GluR2B receptor is encoded by the DNA sequence (SEQ ID NO:1) illustrated in FIGS. 1(A)-1(K). In an obvious alternative, the DNA sequences coding for the selected receptor may be a synonymous codon equivalent of the illustrated DNA sequences. 
     The illustrated DNA sequence constitutes the cDNA sequence identified in human brain cDNA libraries in the manner exemplified herein. Having herein provided the nucleotide sequence of the human GluR2B receptor, however, it will be appreciated that polynucleotides encoding the receptor can be obtained by other routes. Automated techniques of gene synthesis and/or amplification can be performed to generate DNA coding therefor. Because of the length of the human GluR2B receptor-encoding DNA, application of automated synthesis may require staged gene construction, in which regions of the gene up to about 300 nucleotides in length are synthesized individually and then ligated in correct succession by overhang complementarity for final assembly. Individually synthesized gene regions can be amplified prior to assembly, using established polymerase chain reaction (PCR) technology. 
     The application of automated gene synthesis techniques provides an opportunity for generating polynucleotides that encode variants of the naturally occurring human GluR2B receptor. It will be appreciated, for example, that polynucleotides coding for the receptor can be generated by substituting synonymous codons for those represented in the naturally occurring polynucleotide sequences herein identified. In addition, polynucleotides coding for human GluR2B receptor variants can be generated which for example incorporate one or more, e.g. 1-10, single amino acid substitutions, deletions or additions. Since it will for the most part be desirable to retain the natural ligand binding profile of the receptor for screening purposes, it is desirable to limit amino acid substitutions, for example to the so-called conservative replacements in which amino acids of like charge are substituted, and to limit substitutions to those sites less critical for receptor activity e.g. within about the first 20 N-terminal residues of the mature receptor, and such other regions as are elucidated upon receptor domain mapping. 
     With appropriate template DNA in hand, the technique of PCR amplification may also be used to directly generate all or part of the final gene. In this case, primers are synthesized which will prime the PCR amplification of the final product, either in one piece, or in several pieces that may be ligated together. This may be via step-wise ligation of blunt ended, amplified DNA fragments, or preferentially via step-wise ligation of fragments containing naturally occurring restriction endonuclease sites. In this application, it is possible to use either cDNA or genomic DNA as the template for the PCR amplification. In the former case, the cDNA template can be obtained from commercially available or self-constructed cDNA libraries of various human brain tissues, including hippocampus and cerebellum. 
     Once obtained, the receptor-encoding DNA is incorporated for expression into any suitable expression vector, and host cells are transfected therewith using conventional procedures, such as DNA-mediated transformation, electroporation, or particle gun transformation. Expression vectors may be selected to provide transformed cell lines that express the receptor-encoding DNA either transiently or in a stable manner. For transient expression, host cells are typically transformed with an expression vector harbouring an origin of replication functional in a mammalian cell. For stable expression, such replication origins are unnecessary, but the vectors will typically harbour a gene coding for a product that confers on the transformants a survival advantage, to enable their selection. Genes coding for such selectable markers include the E. coli gpt gene which confers resistance to mycophenolic acid, the neo gene from transposon Tn5 which confers resistance to the antibiotic G418 and to neomycin, the dhfr sequence from murine cells or E. coli which changes the phenotype of DHFR- cells into DHFR+ cells, and the tk gene of herpes simplex virus, which makes TK- cells phenotypically TK+ cells. Both transient expression and stable expression can provide transformed cell lines, and membrane preparations derived therefrom, for use in ligand screening assays. 
     For use in screening assays, cells transiently expressing the receptor-encoding DNA can be stored frozen for later use, but because the rapid rate of plasmid replication will lead ultimately to cell death, usually in a few days, the transformed cells should be used as soon as possible. Such assays may be performed either with intact cells, or with membrane preparations derived from such cells. The membrane preparations typically provide a more convenient substrate for the ligand binding experiments, and are therefore preferred as binding substrates. To prepare membrane preparations for screening purposes, i.e., ligand binding experiments, frozen intact cells are homogenized while in cold water suspension and a membrane pellet is collected after centrifugation. The pellet is then washed in cold water, and dialyzed to remove endogenous EAA ligands such as glutamate, that would otherwise compete for binding in the assays. The dialyzed membranes may then be used as such, or after storage in lyophilized form, in the ligand binding assays. Alternatively, intact, fresh cells harvested about two days after transient transfection or after about the same period following fresh plating of stably transfected cells, can be used for ligand binding assays by the same methods as used for membrane preparations. When cells are used, the cells must be harvested by more gentle centrifugation so as not to damage them, and all washing must be done in a buffered medium, for example in phosphate-buffered saline, to avoid osmotic shock and rupture of the cells. 
     The interaction e.g. the binding, of a substance, i.e., a test ligand, to human GluR2B receptor of the invention is evaluated typically using a predetermined amount of cell-derived membrane (measured for example by protein determination), generally from about 25 ug to 100 ug. Generally, competitive binding assays will be useful to evaluate the affinity of a test compound relative to AMPA. This competitive binding assay can be performed by incubating the membrane preparation with radiolabelled AMPA, for example [3H]-AMPA, in the presence of unlabelled test compound added at varying concentrations. Following incubation, either displaced or bound radiolabelled AMPA can be recovered and measured, to determine the relative binding affinities of the test compound and AMPA for the particular receptor used as substrate. In this way, the affinities of various compounds for the AMPA-binding human EAA receptors can be measured. Alternatively, a radiolabelled analogue of glutamate may be employed in place of radiolabelled AMPA, as competing ligand. 
     As an alternative to using cells that express receptor-encoding DNA, ligand characterization may also be performed using cells for example Xenopus oocytes, that yield functional membrane-bound receptor following introduction by injection either of receptor-encoding messenger RNA into the oocyte cytoplasm, or of receptor-encoding DNA into the oocyte nucleus. To generate the messenger RNA of cytoplasmic delivery, the receptor-encoding DNA is typically subcloned first into a plasmidic vector adjacent a suitable promoter region, such as the T3 or T7 bacteriophage promoters, to enable transcription into RNA message. RNA is then transcribed from the inserted gene in vitro, collected and then injected into Xenopus oocytes. Following the injection of nL volumes of an RNA solution, the oocytes are left to incubate for up to several days, and are then tested for the ability to respond to a particular ligand molecule supplied in a bathing solution. Since functional EAA receptors act in part by operating a membrane channel through which ions may selectively pass, the functioning of the receptor in response to a particular ligand molecule in the bathing solution may typically be measured as an electrical current utilizing microelectrodes inserted into the cell, in the established manner. 
     In addition to using the receptor-encoding DNA to construct cell lines useful for ligand screening, expression of the DNA can, according to another aspect of the invention, be performed to produce fragments of the receptor in soluble form, for structure investigation, to raise antibodies and for other experimental uses. It is expected that the portion of the human GluR2B receptor responsible for AMPA-binding resides on the outside of the cell, i.e., is extracellular. It is therefore desirable in the first instance to facilitate the characterization of the receptor-ligand interaction by providing this extracellular ligand-binding domain in quantity and in isolated form, i.e., free from the remainder of the receptor. To accomplish this, the full-length human GluR receptor-encoding DNA may be modified by site-directed mutagenesis, so as to introduce a translational stop codon into the extracellular N-terminal region, immediately before the sequence encoding the first transmembrane domain (TM1), i.e., before residue 525 as shown in FIGS. 1(A)-1(K) (SEQ ID NOS. 1 and 2). Since there will no longer be produced any transmembrane domain(s) to &#34;anchor&#34; the receptor into the membrane, expression of the modified gene will result in the secretion, in soluble form, of only the extracellular ligand-binding domain. Standard ligand-binding assays may then be performed to ascertain the degree of binding of a candidate compound to the extracellular domain so produced. It may of course be necessary, using site-directed mutagenesis, to produce several different versions of the extracellular regions, in order to optimize the degree of ligand binding to the isolated domains. 
     Alternatively, it may be desirable to produce an extracellular domain of the receptor which is not derived from the amino-terminus of the mature protein, but rather from the carboxy-terminus instead, for example domains immediately following the fourth transmembrane domain (TM4), i.e., residing between amino acid residues 813-862 inclusive (FIG. 1) (SEQ ID NOS. 1 and 2). In this case, site-directed mutagenesis and/or PCR-based amplification techniques may readily be used to provide a defined fragment of the gene encoding the receptor domain of interest. Such a DNA sequence may be used to direct the expression of the desired receptor fragment, either intracellularly, or in secreted fashion, provided that the DNA encoding the gene fragment is inserted adjacent to a translation start codon provided by the expression vector, and that the required translation reading frame is carefully conserved. 
     It will be appreciated that the production of such AMPA-binding receptor fragments may be accomplished in a variety of host cells. Mammalian cells such as CHO cells may be used for this purpose, the expression typically being driven by an expression promoter capable of high-level expression, for example the CMV (cytomegalovirus) promoter. Alternately, non-mammalian cells, such as insect Sf9 (Spodoptera frugiperda) cells may be used, with the expression typically being driven by expression promoters of the baculovirus, for example the strong, late polyhedrin protein promoter. Filamentous fungal expression systems may also be used to secrete large quantities of such extracellular domains of the EAA receptor. Aspergillus nidulans, for example, with the expression being driven by the alcA promoter, would constitute such an acceptable system. In addition to such expression hosts, it will be further appreciated that any prokaryotic or other eukaryotic expression system capable of expressing heterologous genes or gene fragments, whether intracellularly or extracellularly would be similarly acceptable. 
     For use particularly in detecting the presence and/or location of a human GluR2B receptor, for example in brain tissue, the present invention also provides, in another of its aspects, labelled antibody to the human GluR2B receptor. To raise such antibodies, there may be used as immunogen either the intact, soluble receptor or an immunogenic fragment thereof, i.e. a fragment capable of eliciting an immune response, produced in a microbial or mammalian cell host as described above or by standard peptide synthesis techniques. Regions of human GluR2B receptor particularly suitable for use as immunogenic fragments include those corresponding in sequence to an extracellular region of the receptor, or a portion of the extracellular region, such as peptides consisting of residues 1-524 or a fragment thereof comprising at least about 10 residues, including particularly fragments containing residues 175-190 or 477-520; and peptides corresponding to the region between transmembrane domains TM-2 and TM-3, such as a peptide consisting of residues 589-600. Peptides consisting of the C-terminal domain (residues 813-862), or fragment thereof, may also be used for the raising of antibodies. 
     The raising of antibodies to the selected human GluR2B receptor or immunogenic fragment can be achieved, for polyclonal antibody production, using immunization protocols of conventional design, and any of a variety of mammalian hosts, such as sheep, goats and rabbits. Alternatively, for monoclonal antibody production, immunocytes such as splenocytes can be recovered from the immunized animal and fused, using hybridoma technology, to a myeloma cells. The fusion products are then screened by culturing in a selection medium, and cells producing antibody are recovered for continuous growth, and antibody recovery. Recovered antibody can then be coupled covalently to a detectable label, such as a radiolabel, enzyme label, luminescent label or the like, using linker technology established for this purpose. 
     In detectably labelled form, e.g. radiolabelled form, DNA or RNA coding for a human GluR2B receptor, and selected regions thereof, may also be used, in accordance with another aspect of the present invention, as hybridization probes for example to identify sequence-related genes resident in the human or other mammalian genomes (or cDNA libraries) or to locate the human GluR2B-encoding DNA in a specimen, such as brain tissue. This can be done using either the intact coding region, or a fragment thereof having radiolabelled e.g.  32  P, nucleotides incorporated therein. To identify the human GluR2B-encoding DNA in a specimen, it is desirable to use either the full length cDNA coding therefor, or a fragment which is unique thereto. With reference to FIG. 1 (SEQ ID NO:1), such nucleotide fragments include those comprising at least about 17 nucleic acids, and otherwise corresponding in sequence to a region coding for the extracellular N-terminal or C-terminal region of the receptor, or representing a 5&#39;-untranslated or 3&#39;-untranslated region thereof. Such oligonucleotide sequences, and the intact gene itself, may also be used of course to clone human GluR2B-related human genes, particularly cDNA equivalents thereof, by standard hybridization techniques. 
     EXAMPLE 1 
     Isolation of DNA Coding for the Human GluR2B Receptor 
     The particular strategy used to clone the human Glu2B receptor is depicted schematically in FIG. 2, and described in greater detail below. 
     cDNA coding for the human GluR2B receptor was identified by probing human hippocampal cDNA that was obtained as an EcoRI-based lambda phage library (lambda ZAP) from Stratagene Cloning Systems (La Jolla, Calif., U.S.A.). The cDNA library was screened using an oligonucleotide probe capable of annealing to the 3&#39; region of the rat GluR2 receptor sequence reported by Keinanen et al, supra. The specific sequence (SEQ ID NO:3) of the 32-P-labelled probe is provided below: 
     5&#39;-GTGAATGTGGAGCCAAGGACTCGGGAAGTAAG-3&#39; 
     The hippocampal cDNA library was screened under the following hybridization conditions; 6×SSC, 25% formamide, 5% Dernhardt&#39;s solution, 0.5% SDS, 100 ug/ml denatured salmon sperm DNA, 42° C. Filters were washed with 2×SSC containing 0.5% SDS at 25° C. for 5 minutes, followed by a 15 minute wash at 50° C. with 2×SSC containing 0.5% SDS. The final wash was with 1×SSC containing 0.5% SDS at 50° C. for 15 minutes. Filters were exposed to X-ray film (Kodak) overnight. Of 10 6  clones screened, only two cDNA inserts were identified, one about 2.7 kb and designated RKCSHG84 and another about 2.9 kb and designated RKCSHG41 (FIG. 2). For sequencing, the &#39;84 and the &#39;41 phages were plaque purified, then excised as phagemids according to the supplier&#39;s specifications, to generate insert-carrying Bluescript-SK variants of the phagemid vector. Sequencing of the &#39;84 clone across its entire sequence revealed a putative ATG initiation codon together with about 314 bases of 5&#39; non-coding region and about 2.4 kb of coding region. Sequencing across the &#39;41 insert revealed a significant region of overlap with the &#39;84 insert, and also revealed a termination codon not found in the &#39;84 insert as well as about 441 bases of 3&#39; non-translated sequence. 
     To provide the entire coding region in an intact clone, the strategy shown in FIG. 2 was employed, to generate the phagemid pBS/HumGluR2B which carries the hGluR2B-encoding DNA as a 3.4 kb EcoRI/PstI insert in a 3.0 kb Bluescript-SK phagemid background. The entire sequence of the EcoRI/PstI insert is provided in FIG. 1 (SEQ ID NO:1). 
     The 6.4 kb phagemid pBS/humGluR2B was deposited, under the terms of the Budapest Treaty, with the American Type Culture Collection in Rockville, Md. USA on Mar. 19, 1992, and has been assigned accession number ATCC 75217. 
     EXAMPLE 2 
     Construction of Genetically Engineered Cells Producing Human GluR2B Receptor 
     For transient expression in mammalian cells, cDNA coding for the human GluR2B receptor was incorporated into the mammalian expression vector pcDNA1, which is available commercially from Invitrogen Corporation (San Diego, Calif., USA; catalogue number V490-20). This is a multifunctional 4.2 kb plasmid vector designed for cDNA expression in eukaryotic systems, and cDNA analysis in prokaryotes. Incorporated on the vector are the CMV promoter and enhancer, splice segment and polyadenylation signal, an SV40 and Polyoma virus origin of replication, and M13 origin to rescue single strand DNA for sequencing and mutagenesis, Sp6 and T7 RNA promoters for the production of sense and antisense RNA transcripts and a Col E1-like high copy plasmid origin. A polylinker is located appropriately downstream of the CMV promoter (and 3&#39; of the T7 promoter). 
     To facilitate incorporation of the GluR2B receptor-encoding cDNA into an expression vector, a NotI site was introduced onto the 5&#39; flank of the Bluescript-SK cDNA insert, and the cDNA insert was then released from pBS/humGluR2B as a 3.4 kb HindIII/NotI fragment, which was then incorporated at the HindIII/NotI sites in the pcDNAI polylinker. Sequencing across the junctions was performed, to confirm proper insert orientation in pcDNA1. The resulting plasmid, designated pcDNA1/humGluR2B, was then introduced for transient expression into a selected mammalian cell host, in this case the monkey-derived, fibroblast like cells of the COS-1 lineage (available from the American Type Culture Collection, Rockville, Md. as ATCC CRL 1650). 
     For transient expression of the GluR2B-encoding DNA, COS-1 cells were transfected with approximately 8 ug DNA (as pcDNA1/humGluR2B) per 10 6  COS cells, by DEAE-mediated DNA transfection and treated with chloroquine according to the procedures described by Maniatis et al, supra. Briefly, COS-1 cells were plated at a density of 5×10 6  cells/dish and then grown for 24 hours in FBS-supplemented DMEM/F12 medium. Medium was then removed and cells were washed in PBS and then in medium. There was then applied on the cells 10 ml of a transfection solution containing DEAE dextran (0.4 mg/ml), 100 uM chloroquine, 10% NuSerum, DNA (0.4 mg/ml) in DMEM/F12 medium. After incubation for 3 hours at 37° C., cells were washed in PBS and medium as just described and then shocked for 1 minute with 10% DMSO in DMEM/F12 medium. Cells were allowed to grow for 2-3 days in 10% FBS-supplemented medium, and at the end of incubation dishes were placed on ice, washed with ice cold PBS and then removed by scraping. Cells were then harvested by centrifugation at 1000 rpm for 10 minutes and the cellular pellet was frozen in liquid nitrogen, for subsequent use in ligand binding assays. Northern blot analysis of a thawed aliquot of frozen cells confirmed expression of receptor-encoding cDNA in cells under storage. 
     In a like manner, stably transfected cell lines can also prepared using two different cell types as host: CHO K1 and CHO Pro5. To construct these cell lines, cDNA coding for human GluR2B was incorporated into the mammalian expression vector pRC/CMV (Invitrogen), which enables stable expression. Insertion at this site placed the cDNA under the expression control of the cytomegalovirus promoter and upstream of the polyadenylation site and terminator of the bovine growth hormone gene, and into a vector background comprising the neomycin resistance gene (driven by the SV40 early promoter) as selectable marker. 
     To introduce plasmids constructed as described above, the host CHO cells are first seeded at a density of 5×10 5  in 10% FBS-supplemented MEM medium. After growth for 24 hours, fresh medium are added to the plates and three hours later, the cells are transfected using the calcium phosphate-DNA co-precipitation procedure (Maniatis et al, supra). Briefly, 3 ug of DNA is mixed and incubated with buffered calcium solution for 10 minutes at room temperature. An equal volume of buffered phosphate solution is added and the suspension is incubated for 15 minutes at room temperature. Next, the incubated suspension is applied to the cells for 4 hours, removed and cells were shocked with medium containing 15% glycerol. Three minutes later, cells are washed with medium and incubated for 24 hours at normal growth conditions. Cells resistant to neomycin are selected in 10% FBS-supplemented alpha-MEM medium containing G418 (1 mg/ml). Individual colonies of G418-resistant cells are isolated about 2-3 weeks later, clonally selected and then propogated for assay purposes. 
     EXAMPLE 3 
     Ligand Binding Assays 
     Transfected cells in the frozen state were resuspended in ice-cold distilted water using a hand homogenizer, sonicated for 5 seconds, and then centrifuged for 20 minutes at 50,000 g. The supernatant was discarded and the membrane pellet stored frozen at -70° C. 
     COS cell membrane pellets were suspended in ice cold 50 mM Tris-HCl (pH 7.55, 5° C.) and centrifuged again at 50,000 g for 10 minutes in order to remove endogenous glutamate that would compete for binding. Pellets were resuspended in ice cold 50 mM Tris-HCl (pH 7.55) buffer and the resultant membrane preparation was used as tissue source for binding experiments described below. Proteins were determined using the Pierce Reagent with BSA as standard. 
     Binding assays were then performed, using an amount of COS-derived membrane equivalent to from 25-100 ug as judged by protein determination and selected radiolabelled ligand. In particular, for AMPA-binding assays, incubation mixtures consisted of 25-100 ug tissue protein and D, L-alpha-[5-methyl-3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid (3H-AMPA, 27.6Ci/mmole, 10 nM final) with 0.1M KSCN and 2.5 mM CaCl 2  in the 1 ml final volume. Non-specific binding was determined in the presence of 1 mM L-glutamate. Samples were incubated on ice for 60 minutes in plastic minivials, and bound and free ligand were separated by centrifugation for 30 minutes at 50,000 g. Pellets were washed twice in 4 ml of the cold incubation buffer, then 5 ml of Beckman Ready-Protein Plus scintillation cocktail was added, for counting. 
     For kainate-binding assays, incubation mixtures consisted of 25-100 ug tissue protein and [vinylidene-3H] kainic acid (58Ci/mmole, 5 nM final) in the cold incubation buffer, 1 ml final volume. Non-specific binding was determined in the presence of 1 mM L-glutamate. Samples were incubated as for the AMPA-binding assays, and bound and free ligand were separated by rapid filtration using a Brandel cell harvester and GF/B filters pre-soaked in ice-cold 0.3% polyethyleneimine. Filters were washed twice in 6 ml of the cold incubation buffer, then placed in scintillation vials with 5 ml of Beckman Ready-Protein Plus scintillation cocktail for counting. 
     Assays performed in this manner, using membrane preparations derived from the human GluR2B receptor-producing COS cells, revealed specific binding of 750-850 fmole/mg protein, at 10 nM [3H]-AMPA (FIG. 4). Mock transfected cells exhibited no specific binding of any of the ligands tested. These results demonstrate clearly that the human GluR2B receptor is binding AMPA with specificity. This activity, coupled with the fact that there is little or no demonstrable binding of either kainate or NMDA, clearly assigns the human GluR2B receptor to be of the AMPA type of EAA receptor. Furthermore, this binding profile indicates that the receptor is binding in an authentic manner, and can therefore reliably predict the ligand binding &#34;signature&#34; of its non-recombinant counterpart from the human brain. These features make the recombinant receptor especially useful for selecting and characterizing ligand compounds which bind to the receptor, and/or for selecting and characterizing compounds which may act by displacing other ligands from the receptor. The isolation of the GluR2B receptor genes in substantially pure form, capable of being expressed as a single, homogeneous receptor species, therefore frees the ligand binding assay from the lack of precision introduced when complex, heterogeneous receptor preparations from human and other mammalian brains are used to attempt such characterizations. 
     
         __________________________________________________________________________
#             SEQUENCE LISTING                                            
  - -  - - (1) GENERAL INFORMATION:                                       
  - -    (iii) NUMBER OF SEQUENCES: 3                                     
  - -  - - (2) INFORMATION FOR SEQ ID NO:1:                               
  - -      (i) SEQUENCE CHARACTERISTICS:                                  
           (A) LENGTH: 3407 base - #pairs                                 
           (B) TYPE: nucleic acid                                         
           (C) STRANDEDNESS: double                                       
           (D) TOPOLOGY: linear                                           
  - -     (ii) MOLECULE TYPE: cDNA                                        
  - -     (ix) FEATURE:                                                   
           (A) NAME/KEY: CDS                                              
           (B) LOCATION: 315..2966                                        
  - -     (ix) FEATURE:                                                   
           (A) NAME/KEY: sig.sub.-- - #peptide                            
           (B) LOCATION: 315..374                                         
  - -     (ix) FEATURE:                                                   
           (A) NAME/KEY: mat.sub.-- - #peptide                            
           (B) LOCATION: 375..2966                                        
  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                         
  - - GAATTCCGTG AGTGCATGGG AGGGTGCTGA ATATTCCGAG ACACTGGGAC CA -         
#CAGCGGCA     60                                                          
   - - GCTCCGCTGA AAACTGCATT CAGCCAGTCC TCCGGACTTC TGGAGCGGGG AC -        
#AGGGCGCA    120                                                          
   - - GGGCATCAGC AGCCACCAGC AGGACCTGGG AAATAGGGAT TCTTCTGCCT CC -        
#ACTTCAGG    180                                                          
   - - TTTTAGCAGC TTGGTGCTAA ATTGCTGTCT CAAAATGCAG AGGATCTAAT TT -        
#GCAGAGGA    240                                                          
   - - AAACAGCCAA AGAAGGAAGA GGAGGAAAAG GAAAAAAAAA GGGGTATATT GT -        
#GGATGCTC    300                                                          
   - - TACTTTTCTT GGAA ATG CAA AAG ATT ATG CAT ATT T - #CT GTC CTC CTT    
TCT      350                                                              
                  Met G - #ln Lys Ile Met His Ile Ser Val Leu Leu Se - #r 
                 -20  - #               -15  - #               -10        
  - - CCT GTT TTA TGG GGA CTG ATT TTT GGT GTC TC - #T TCT AAC AGC ATA CAG 
     398                                                                  
 Pro Val Leu Trp Gly Leu Ile Phe Gly Val Se - #r Ser Asn Ser Ile Gln      
              -5     - #              1    - #           5                
  - - ATA GGG GGG CTA TTT CCT AGG GGC GCC GAT CA - #A GAA TAC AGT GCA TTT 
     446                                                                  
 Ile Gly Gly Leu Phe Pro Arg Gly Ala Asp Gl - #n Glu Tyr Ser Ala Phe      
      10             - #     15             - #     20                    
  - - CGA GTA GGG ATG GTT CAG TTT TCC ACT TCG GA - #G TTC AGA CTG ACA CCC 
     494                                                                  
 Arg Val Gly Met Val Gln Phe Ser Thr Ser Gl - #u Phe Arg Leu Thr Pro      
  25                 - # 30                 - # 35                 - # 40 
  - - CAC ATC GAC AAT TTG GAG GTG GCA AAC AGC TT - #C GCA GTC ACT AAT GCT 
     542                                                                  
 His Ile Asp Asn Leu Glu Val Ala Asn Ser Ph - #e Ala Val Thr Asn Ala      
                  45 - #                 50 - #                 55        
  - - TTC TGC TCC CAG TTT TCG AGA GGA GTC TAT GC - #T ATT TTT GGA TTT TAT 
     590                                                                  
 Phe Cys Ser Gln Phe Ser Arg Gly Val Tyr Al - #a Ile Phe Gly Phe Tyr      
              60     - #             65     - #             70            
  - - GAC AAG AAG TCT GTA AAT ACC ATC ACA TCA TT - #T TGC GGA ACA CTC CAC 
     638                                                                  
 Asp Lys Lys Ser Val Asn Thr Ile Thr Ser Ph - #e Cys Gly Thr Leu His      
          75         - #         80         - #         85                
  - - GTC TCC TTC ATC ACT CCC AGC TTC CCA ACA GA - #T GGC ACA CAT CCA TTT 
     686                                                                  
 Val Ser Phe Ile Thr Pro Ser Phe Pro Thr As - #p Gly Thr His Pro Phe      
      90             - #     95             - #    100                    
  - - GTC ATT CAG ATG AGA CCC GAC CTC AAA GGA GC - #T CTC CTT AGC TTG ATT 
     734                                                                  
 Val Ile Gln Met Arg Pro Asp Leu Lys Gly Al - #a Leu Leu Ser Leu Ile      
 105                 1 - #10                 1 - #15                 1 -  
#20                                                                       
   - - GAA TAC TAT CAA TGG GAC AAG TTT GCA TAC CT - #C TAT GAC AGT GAC    
AGA      782                                                              
  Glu Tyr Tyr Gln Trp Asp Lys Phe Ala Tyr Le - #u Tyr Asp Ser Asp Arg     
                 125  - #               130  - #               135        
  - - GGC TTA TCA ACA CTG CAA GCT GTG CTG GAT TC - #T GCT GCT GAA AAG AAA 
     830                                                                  
 Gly Leu Ser Thr Leu Gln Ala Val Leu Asp Se - #r Ala Ala Glu Lys Lys      
             140      - #           145      - #           150            
  - - TGG CAA GTG ACT GCT ATC AAT GTG GGA AAC AT - #T AAC AAT GAC AAG AAA 
     878                                                                  
 Trp Gln Val Thr Ala Ile Asn Val Gly Asn Il - #e Asn Asn Asp Lys Lys      
         155          - #       160          - #       165                
  - - GAT GAG ATG TAC CGA TCA CTT TTT CAA GAT CT - #G GAG TTA AAA AAG GAA 
     926                                                                  
 Asp Glu Met Tyr Arg Ser Leu Phe Gln Asp Le - #u Glu Leu Lys Lys Glu      
     170              - #   175              - #   180                    
  - - CGG CGT GTA ATT CTG GAC TGT GAA AGG GAT AA - #A GTA AAC GAC ATT GTA 
     974                                                                  
 Arg Arg Val Ile Leu Asp Cys Glu Arg Asp Ly - #s Val Asn Asp Ile Val      
 185                 1 - #90                 1 - #95                 2 -  
#00                                                                       
   - - GAC CAG GTT ATT ACC ATT GGA AAA CAC GTT AA - #A GGG TAC CAC TAC    
ATC     1022                                                              
  Asp Gln Val Ile Thr Ile Gly Lys His Val Ly - #s Gly Tyr His Tyr Ile     
                 205  - #               210  - #               215        
  - - ATT GCA AAT CTG GGA TTT ACT GAT GGA GAC CT - #A TTA AAA ATC CAG TTT 
    1070                                                                  
 Ile Ala Asn Leu Gly Phe Thr Asp Gly Asp Le - #u Leu Lys Ile Gln Phe      
             220      - #           225      - #           230            
  - - GGA GGT GCA AAT GTC TCT GGA TTT CAG ATA GT - #G GAC TAT GAT GAT TCG 
    1118                                                                  
 Gly Gly Ala Asn Val Ser Gly Phe Gln Ile Va - #l Asp Tyr Asp Asp Ser      
         235          - #       240          - #       245                
  - - TTG GTA TCT AAA TTT ATA GAA AGA TGG TCA AC - #A CTG GAA GAA AAA GAA 
    1166                                                                  
 Leu Val Ser Lys Phe Ile Glu Arg Trp Ser Th - #r Leu Glu Glu Lys Glu      
     250              - #   255              - #   260                    
  - - TAC CCT GGA GCT CAC ACA ACA ACA ATT AAG TA - #T ACT TCT GCT CTG ACC 
    1214                                                                  
 Tyr Pro Gly Ala His Thr Thr Thr Ile Lys Ty - #r Thr Ser Ala Leu Thr      
 265                 2 - #70                 2 - #75                 2 -  
#80                                                                       
   - - TAT GAT GCC GTT CAA GTG ATG ACT GAA GCC TT - #C CGC AAC CTA AGG    
AAG     1262                                                              
  Tyr Asp Ala Val Gln Val Met Thr Glu Ala Ph - #e Arg Asn Leu Arg Lys     
                 285  - #               290  - #               295        
  - - CAA AGA ATT GAA ATC TCC CGA AGG GGG AAT GC - #A GGA GAC TGT CTG GCA 
    1310                                                                  
 Gln Arg Ile Glu Ile Ser Arg Arg Gly Asn Al - #a Gly Asp Cys Leu Ala      
             300      - #           305      - #           310            
  - - AAC CCA GCA GTG CCC TGG GGA CAA GGT GTA GA - #A ATA GAA AGG GCC CTC 
    1358                                                                  
 Asn Pro Ala Val Pro Trp Gly Gln Gly Val Gl - #u Ile Glu Arg Ala Leu      
         315          - #       320          - #       325                
  - - AAA CAG GTT CAG GTT GAA GGT CTC TCA GGA AA - #T ATA AAG TTT GAC CAG 
    1406                                                                  
 Lys Gln Val Gln Val Glu Gly Leu Ser Gly As - #n Ile Lys Phe Asp Gln      
     330              - #   335              - #   340                    
  - - AAT GGA AAA AGA ATA AAC TAT ACA ATT AAC AT - #C ATG GAG CTC AAA ACT 
    1454                                                                  
 Asn Gly Lys Arg Ile Asn Tyr Thr Ile Asn Il - #e Met Glu Leu Lys Thr      
 345                 3 - #50                 3 - #55                 3 -  
#60                                                                       
   - - AAT GGG CCC CGG AAG ATT GGC TAC TGG AGT GA - #A GTG GAC AAA ATG    
GTT     1502                                                              
  Asn Gly Pro Arg Lys Ile Gly Tyr Trp Ser Gl - #u Val Asp Lys Met Val     
                 365  - #               370  - #               375        
  - - GTT ACC CTT ACT GAG CTC CCT TCT GGA AAT GA - #C ACC TCT GGG CTT GAG 
    1550                                                                  
 Val Thr Leu Thr Glu Leu Pro Ser Gly Asn As - #p Thr Ser Gly Leu Glu      
             380      - #           385      - #           390            
  - - AAT AAG ACT GTT GTT GTC ACC ACA ATT TTG GA - #A TCT CCG TAT GTT ATG 
    1598                                                                  
 Asn Lys Thr Val Val Val Thr Thr Ile Leu Gl - #u Ser Pro Tyr Val Met      
         395          - #       400          - #       405                
  - - ATG AAG AAA AAT CAT GAA ATG CTT GAA GGC AA - #T GAG CGC TAT GAG GGC 
    1646                                                                  
 Met Lys Lys Asn His Glu Met Leu Glu Gly As - #n Glu Arg Tyr Glu Gly      
     410              - #   415              - #   420                    
  - - TAC TGT GTT GAC CTG GCT GCA GAA ATC GCC AA - #A CAT TGT GGG TTC AAG 
    1694                                                                  
 Tyr Cys Val Asp Leu Ala Ala Glu Ile Ala Ly - #s His Cys Gly Phe Lys      
 425                 4 - #30                 4 - #35                 4 -  
#40                                                                       
   - - TAC AAG TTG ACA ATT GTT GGT GAT GGC AAG TA - #T GGG GCC AGG GAT    
GCA     1742                                                              
  Tyr Lys Leu Thr Ile Val Gly Asp Gly Lys Ty - #r Gly Ala Arg Asp Ala     
                 445  - #               450  - #               455        
  - - GAC ACG AAA ATT TGG AAT GGG ATG GTT GGA GA - #A CTT GTA TAT GGG AAA 
    1790                                                                  
 Asp Thr Lys Ile Trp Asn Gly Met Val Gly Gl - #u Leu Val Tyr Gly Lys      
             460      - #           465      - #           470            
  - - GCT GAT ATT GCA ATT GCT CCA TTA ACT ATT AC - #C CTT GTG AGA GAA GAG 
    1838                                                                  
 Ala Asp Ile Ala Ile Ala Pro Leu Thr Ile Th - #r Leu Val Arg Glu Glu      
         475          - #       480          - #       485                
  - - GTG ATT GAC TTC TCA AAG CCC TTC ATG AGC CT - #C GGG ATA TCT ATC ATG 
    1886                                                                  
 Val Ile Asp Phe Ser Lys Pro Phe Met Ser Le - #u Gly Ile Ser Ile Met      
     490              - #   495              - #   500                    
  - - ATC AAG AAG CCT CAG AAG TCC AAA CCA GGA GT - #G TTT TCC TTT CTT GAT 
    1934                                                                  
 Ile Lys Lys Pro Gln Lys Ser Lys Pro Gly Va - #l Phe Ser Phe Leu Asp      
 505                 5 - #10                 5 - #15                 5 -  
#20                                                                       
   - - CCT TTA GCC TAT GAG ATC TGG ATG TGC ATT GT - #T TTT GCC TAC ATT    
GGG     1982                                                              
  Pro Leu Ala Tyr Glu Ile Trp Met Cys Ile Va - #l Phe Ala Tyr Ile Gly     
                 525  - #               530  - #               535        
  - - GTC AGT GTA GTT TTA TTC CTG GTC AGC AGA TT - #T AGC CCC TAC GAG TGG 
    2030                                                                  
 Val Ser Val Val Leu Phe Leu Val Ser Arg Ph - #e Ser Pro Tyr Glu Trp      
             540      - #           545      - #           550            
  - - CAC ACT GAG GAG TTT GAA GAT GGA AGA GAA AC - #A CAA AGT AGT GAA TCA 
    2078                                                                  
 His Thr Glu Glu Phe Glu Asp Gly Arg Glu Th - #r Gln Ser Ser Glu Ser      
         555          - #       560          - #       565                
  - - ACT AAT GAA TTT GGG ATT TTT AAT AGT CTC TG - #G TTT TCC TTG GGT GCC 
    2126                                                                  
 Thr Asn Glu Phe Gly Ile Phe Asn Ser Leu Tr - #p Phe Ser Leu Gly Ala      
     570              - #   575              - #   580                    
  - - TTT ATG CGG CAA GGA TGC GAT ATT TCG CCA AG - #A TCC CTC TCT GGG CGC 
    2174                                                                  
 Phe Met Arg Gln Gly Cys Asp Ile Ser Pro Ar - #g Ser Leu Ser Gly Arg      
 585                 5 - #90                 5 - #95                 6 -  
#00                                                                       
   - - ATT GTT GGA GGT GTG TGG TGG TTC TTT ACC CT - #G ATC ATA ATC TCC    
TCC     2222                                                              
  Ile Val Gly Gly Val Trp Trp Phe Phe Thr Le - #u Ile Ile Ile Ser Ser     
                 605  - #               610  - #               615        
  - - TAC ACG GCT AAC TTA GCT GCC TTC CTG ACT GT - #A GAG AGG ATG GTG TCT 
    2270                                                                  
 Tyr Thr Ala Asn Leu Ala Ala Phe Leu Thr Va - #l Glu Arg Met Val Ser      
             620      - #           625      - #           630            
  - - CCC ATC GAA AGT GCT GAG GAT CTT TCT AAG CA - #A ACA GAA ATT GCT TAT 
    2318                                                                  
 Pro Ile Glu Ser Ala Glu Asp Leu Ser Lys Gl - #n Thr Glu Ile Ala Tyr      
         635          - #       640          - #       645                
  - - GGA ACA TTA GAC TCT GGC TCC ACT AAA GAG TT - #T TTC AGG AGA TCT AAA 
    2366                                                                  
 Gly Thr Leu Asp Ser Gly Ser Thr Lys Glu Ph - #e Phe Arg Arg Ser Lys      
     650              - #   655              - #   660                    
  - - ATT GCA GTG TTT GAT AAA ATG TGG ACC TAC AT - #G CGG AGT GCG GAG CCC 
    2414                                                                  
 Ile Ala Val Phe Asp Lys Met Trp Thr Tyr Me - #t Arg Ser Ala Glu Pro      
 665                 6 - #70                 6 - #75                 6 -  
#80                                                                       
   - - TCT GTG TTT GTG AGG ACT ACG GCC GAA GGG GT - #G GCT AGA GTG CGG    
AAG     2462                                                              
  Ser Val Phe Val Arg Thr Thr Ala Glu Gly Va - #l Ala Arg Val Arg Lys     
                 685  - #               690  - #               695        
  - - TCC AAA GGG AAA TAT GCC TAC TTG TTG GAG TC - #C ACG ATG AAC GAG TAC 
    2510                                                                  
 Ser Lys Gly Lys Tyr Ala Tyr Leu Leu Glu Se - #r Thr Met Asn Glu Tyr      
             700      - #           705      - #           710            
  - - ATT GAG CAA AGG AAG CCT TGC GAC ACC ATG AA - #A GTT GGT GGA AAC CTG 
    2558                                                                  
 Ile Glu Gln Arg Lys Pro Cys Asp Thr Met Ly - #s Val Gly Gly Asn Leu      
         715          - #       720          - #       725                
  - - GAT TCC AAA GGC TAT GGC ATC GCA ACA CCT AA - #A GGA TCC TCA TTA GGA 
    2606                                                                  
 Asp Ser Lys Gly Tyr Gly Ile Ala Thr Pro Ly - #s Gly Ser Ser Leu Gly      
     730              - #   735              - #   740                    
  - - ACC CCA GTA AAT CTT GCA GTA TTG AAA CTC AG - #T GAG CAA GGC GTC TTA 
    2654                                                                  
 Thr Pro Val Asn Leu Ala Val Leu Lys Leu Se - #r Glu Gln Gly Val Leu      
 745                 7 - #50                 7 - #55                 7 -  
#60                                                                       
   - - GAC AAG CTG AAA AAC AAA TGG TGG TAC GAT AA - #A GGT GAA TGT GGA    
GCC     2702                                                              
  Asp Lys Leu Lys Asn Lys Trp Trp Tyr Asp Ly - #s Gly Glu Cys Gly Ala     
                 765  - #               770  - #               775        
  - - AAG GAC TCT GGA AGT AAG GAA AAG ACC AGT GC - #C CTC AGT CTG AGC AAC 
    2750                                                                  
 Lys Asp Ser Gly Ser Lys Glu Lys Thr Ser Al - #a Leu Ser Leu Ser Asn      
             780      - #           785      - #           790            
  - - GTT GCT GGA GTA TTC TAC ATC CTT GTC GGG GG - #C CTT GGT TTG GCA ATG 
    2798                                                                  
 Val Ala Gly Val Phe Tyr Ile Leu Val Gly Gl - #y Leu Gly Leu Ala Met      
         795          - #       800          - #       805                
  - - CTG GTG GCT TTG ATT GAG TTC TGT TAC AAG TC - #A AGG GCC GAG GCG AAA 
    2846                                                                  
 Leu Val Ala Leu Ile Glu Phe Cys Tyr Lys Se - #r Arg Ala Glu Ala Lys      
     810              - #   815              - #   820                    
  - - CGA ATG AAG GTG GCA AAG AAT GCA CAG AAT AT - #T AAC CCA TCT TCC TCG 
    2894                                                                  
 Arg Met Lys Val Ala Lys Asn Ala Gln Asn Il - #e Asn Pro Ser Ser Ser      
 825                 8 - #30                 8 - #35                 8 -  
#40                                                                       
   - - CAG AAT TCA CAG AAT TTT GCA ACT TAT AAG GA - #A GGT TAC AAC GTA    
TAT     2942                                                              
  Gln Asn Ser Gln Asn Phe Ala Thr Tyr Lys Gl - #u Gly Tyr Asn Val Tyr     
                 845  - #               850  - #               855        
  - - GGC ATC GAA AGT GTT AAA ATT TAGGGGATGA CCTTGAATG - #A TGCCATGAGG    
    2993                                                                  
 Gly Ile Glu Ser Val Lys Ile                                              
             860                                                          
  - - AACAAGGCAA GGCTGTCAAT TACAGGAAGT ACTGGAGAAA ATGGACGTGT TA -         
#TGACTCCA   3053                                                          
   - - GAATTTCCCA AAGCNGTGCA TGCTGTCCCT TACGTGAGTC CTGGCATGGG AA -        
#TGAATGTC   3113                                                          
   - - AGTGTGACTG ATCTCTCGTG ATTGATAAGA ACCTTTTGAG TGCCTTACAC AA -        
#TGGTTTTC   3173                                                          
   - - TTGTGTGTTT ATTGTCAAAG TGGTGAGAGG CATCCAGTAT CTTGAAGACT TT -        
#TCTTTCAG   3233                                                          
   - - CCAAGAATTC TTAAATATGT GGAGTTCATC TTGAATTGTA AGGAATGATT AA -        
#TTAAAACA   3293                                                          
   - - CAACATCTTT TTCTACTCGA GTTACAGACA AAGCGTGGTG GACATGCACA GC -        
#TAACATGG   3353                                                          
   - - AAGTACTATA ATTTACCTGA AGTCTTTGTA CAGACAACAA ACCTGTTTCT GC - #AG    
     3407                                                                 
  - -  - - (2) INFORMATION FOR SEQ ID NO:2:                               
  - -      (i) SEQUENCE CHARACTERISTICS:                                  
           (A) LENGTH: 883 amino - #acids                                 
           (B) TYPE: amino acid                                           
           (D) TOPOLOGY: linear                                           
  - -     (ii) MOLECULE TYPE: protein                                     
  - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:                         
  - - Met Gln Lys Ile Met His Ile Ser Val Leu Le - #u Ser Pro Val Leu Trp 
20                 - - #15                 - - #10                  - #-5 
  - - Gly Leu Ile Phe Gly Val Ser Ser Asn Ser Il - #e Gln Ile Gly Gly Leu 
                   - #1               5   - #               10            
  - - Phe Pro Arg Gly Ala Asp Gln Glu Tyr Ser Al - #a Phe Arg Val Gly Met 
          15         - #         20         - #         25                
  - - Val Gln Phe Ser Thr Ser Glu Phe Arg Leu Th - #r Pro His Ile Asp Asn 
      30             - #     35             - #     40                    
  - - Leu Glu Val Ala Asn Ser Phe Ala Val Thr As - #n Ala Phe Cys Ser Gln 
  45                 - # 50                 - # 55                 - # 60 
  - - Phe Ser Arg Gly Val Tyr Ala Ile Phe Gly Ph - #e Tyr Asp Lys Lys Ser 
                  65 - #                 70 - #                 75        
  - - Val Asn Thr Ile Thr Ser Phe Cys Gly Thr Le - #u His Val Ser Phe Ile 
              80     - #             85     - #             90            
  - - Thr Pro Ser Phe Pro Thr Asp Gly Thr His Pr - #o Phe Val Ile Gln Met 
          95         - #        100         - #        105                
  - - Arg Pro Asp Leu Lys Gly Ala Leu Leu Ser Le - #u Ile Glu Tyr Tyr Gln 
     110              - #   115              - #   120                    
  - - Trp Asp Lys Phe Ala Tyr Leu Tyr Asp Ser As - #p Arg Gly Leu Ser Thr 
 125                 1 - #30                 1 - #35                 1 -  
#40                                                                       
   - - Leu Gln Ala Val Leu Asp Ser Ala Ala Glu Ly - #s Lys Trp Gln Val    
Thr                                                                       
                  145  - #               150  - #               155       
  - - Ala Ile Asn Val Gly Asn Ile Asn Asn Asp Ly - #s Lys Asp Glu Met Tyr 
             160      - #           165      - #           170            
  - - Arg Ser Leu Phe Gln Asp Leu Glu Leu Lys Ly - #s Glu Arg Arg Val Ile 
         175          - #       180          - #       185                
  - - Leu Asp Cys Glu Arg Asp Lys Val Asn Asp Il - #e Val Asp Gln Val Ile 
     190              - #   195              - #   200                    
  - - Thr Ile Gly Lys His Val Lys Gly Tyr His Ty - #r Ile Ile Ala Asn Leu 
 205                 2 - #10                 2 - #15                 2 -  
#20                                                                       
   - - Gly Phe Thr Asp Gly Asp Leu Leu Lys Ile Gl - #n Phe Gly Gly Ala    
Asn                                                                       
                  225  - #               230  - #               235       
  - - Val Ser Gly Phe Gln Ile Val Asp Tyr Asp As - #p Ser Leu Val Ser Lys 
             240      - #           245      - #           250            
  - - Phe Ile Glu Arg Trp Ser Thr Leu Glu Glu Ly - #s Glu Tyr Pro Gly Ala 
         255          - #       260          - #       265                
  - - His Thr Thr Thr Ile Lys Tyr Thr Ser Ala Le - #u Thr Tyr Asp Ala Val 
     270              - #   275              - #   280                    
  - - Gln Val Met Thr Glu Ala Phe Arg Asn Leu Ar - #g Lys Gln Arg Ile Glu 
 285                 2 - #90                 2 - #95                 3 -  
#00                                                                       
   - - Ile Ser Arg Arg Gly Asn Ala Gly Asp Cys Le - #u Ala Asn Pro Ala    
Val                                                                       
                  305  - #               310  - #               315       
  - - Pro Trp Gly Gln Gly Val Glu Ile Glu Arg Al - #a Leu Lys Gln Val Gln 
             320      - #           325      - #           330            
  - - Val Glu Gly Leu Ser Gly Asn Ile Lys Phe As - #p Gln Asn Gly Lys Arg 
         335          - #       340          - #       345                
  - - Ile Asn Tyr Thr Ile Asn Ile Met Glu Leu Ly - #s Thr Asn Gly Pro Arg 
     350              - #   355              - #   360                    
  - - Lys Ile Gly Tyr Trp Ser Glu Val Asp Lys Me - #t Val Val Thr Leu Thr 
 365                 3 - #70                 3 - #75                 3 -  
#80                                                                       
   - - Glu Leu Pro Ser Gly Asn Asp Thr Ser Gly Le - #u Glu Asn Lys Thr    
Val                                                                       
                  385  - #               390  - #               395       
  - - Val Val Thr Thr Ile Leu Glu Ser Pro Tyr Va - #l Met Met Lys Lys Asn 
             400      - #           405      - #           410            
  - - His Glu Met Leu Glu Gly Asn Glu Arg Tyr Gl - #u Gly Tyr Cys Val Asp 
         415          - #       420          - #       425                
  - - Leu Ala Ala Glu Ile Ala Lys His Cys Gly Ph - #e Lys Tyr Lys Leu Thr 
     430              - #   435              - #   440                    
  - - Ile Val Gly Asp Gly Lys Tyr Gly Ala Arg As - #p Ala Asp Thr Lys Ile 
 445                 4 - #50                 4 - #55                 4 -  
#60                                                                       
   - - Trp Asn Gly Met Val Gly Glu Leu Val Tyr Gl - #y Lys Ala Asp Ile    
Ala                                                                       
                  465  - #               470  - #               475       
  - - Ile Ala Pro Leu Thr Ile Thr Leu Val Arg Gl - #u Glu Val Ile Asp Phe 
             480      - #           485      - #           490            
  - - Ser Lys Pro Phe Met Ser Leu Gly Ile Ser Il - #e Met Ile Lys Lys Pro 
         495          - #       500          - #       505                
  - - Gln Lys Ser Lys Pro Gly Val Phe Ser Phe Le - #u Asp Pro Leu Ala Tyr 
     510              - #   515              - #   520                    
  - - Glu Ile Trp Met Cys Ile Val Phe Ala Tyr Il - #e Gly Val Ser Val Val 
 525                 5 - #30                 5 - #35                 5 -  
#40                                                                       
   - - Leu Phe Leu Val Ser Arg Phe Ser Pro Tyr Gl - #u Trp His Thr Glu    
Glu                                                                       
                  545  - #               550  - #               555       
  - - Phe Glu Asp Gly Arg Glu Thr Gln Ser Ser Gl - #u Ser Thr Asn Glu Phe 
             560      - #           565      - #           570            
  - - Gly Ile Phe Asn Ser Leu Trp Phe Ser Leu Gl - #y Ala Phe Met Arg Gln 
         575          - #       580          - #       585                
  - - Gly Cys Asp Ile Ser Pro Arg Ser Leu Ser Gl - #y Arg Ile Val Gly Gly 
     590              - #   595              - #   600                    
  - - Val Trp Trp Phe Phe Thr Leu Ile Ile Ile Se - #r Ser Tyr Thr Ala Asn 
 605                 6 - #10                 6 - #15                 6 -  
#20                                                                       
   - - Leu Ala Ala Phe Leu Thr Val Glu Arg Met Va - #l Ser Pro Ile Glu    
Ser                                                                       
                  625  - #               630  - #               635       
  - - Ala Glu Asp Leu Ser Lys Gln Thr Glu Ile Al - #a Tyr Gly Thr Leu Asp 
             640      - #           645      - #           650            
  - - Ser Gly Ser Thr Lys Glu Phe Phe Arg Arg Se - #r Lys Ile Ala Val Phe 
         655          - #       660          - #       665                
  - - Asp Lys Met Trp Thr Tyr Met Arg Ser Ala Gl - #u Pro Ser Val Phe Val 
     670              - #   675              - #   680                    
  - - Arg Thr Thr Ala Glu Gly Val Ala Arg Val Ar - #g Lys Ser Lys Gly Lys 
 685                 6 - #90                 6 - #95                 7 -  
#00                                                                       
   - - Tyr Ala Tyr Leu Leu Glu Ser Thr Met Asn Gl - #u Tyr Ile Glu Gln    
Arg                                                                       
                  705  - #               710  - #               715       
  - - Lys Pro Cys Asp Thr Met Lys Val Gly Gly As - #n Leu Asp Ser Lys Gly 
             720      - #           725      - #           730            
  - - Tyr Gly Ile Ala Thr Pro Lys Gly Ser Ser Le - #u Gly Thr Pro Val Asn 
         735          - #       740          - #       745                
  - - Leu Ala Val Leu Lys Leu Ser Glu Gln Gly Va - #l Leu Asp Lys Leu Lys 
     750              - #   755              - #   760                    
  - - Asn Lys Trp Trp Tyr Asp Lys Gly Glu Cys Gl - #y Ala Lys Asp Ser Gly 
 765                 7 - #70                 7 - #75                 7 -  
#80                                                                       
   - - Ser Lys Glu Lys Thr Ser Ala Leu Ser Leu Se - #r Asn Val Ala Gly    
Val                                                                       
                  785  - #               790  - #               795       
  - - Phe Tyr Ile Leu Val Gly Gly Leu Gly Leu Al - #a Met Leu Val Ala Leu 
             800      - #           805      - #           810            
  - - Ile Glu Phe Cys Tyr Lys Ser Arg Ala Glu Al - #a Lys Arg Met Lys Val 
         815          - #       820          - #       825                
  - - Ala Lys Asn Ala Gln Asn Ile Asn Pro Ser Se - #r Ser Gln Asn Ser Gln 
     830              - #   835              - #   840                    
  - - Asn Phe Ala Thr Tyr Lys Glu Gly Tyr Asn Va - #l Tyr Gly Ile Glu Ser 
 845                 8 - #50                 8 - #55                 8 -  
#60                                                                       
   - - Val Lys Ile                                                        
   - -  - - (2) INFORMATION FOR SEQ ID NO:3:                              
   - -      (i) SEQUENCE CHARACTERISTICS:                                 
            (A) LENGTH: 32 base - #pairs                                  
            (B) TYPE: nucleic acid                                        
            (C) STRANDEDNESS: single                                      
            (D) TOPOLOGY: linear                                          
   - -     (ii) MOLECULE TYPE: Other nucleic acid;                        
            (A) DESCRIPTION: Synthetic - # DNA oligonucleotide            
   - -     (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                        
   - - GTGAATGTGG AGCCAAGGAC TCGGGAAGTA AG       - #                  - # 
         32                                                               
__________________________________________________________________________